CN1156462C - 抗精神病的环状n-芳烷基胺 - Google Patents

抗精神病的环状n-芳烷基胺 Download PDF

Info

Publication number
CN1156462C
CN1156462C CNB008111413A CN00811141A CN1156462C CN 1156462 C CN1156462 C CN 1156462C CN B008111413 A CNB008111413 A CN B008111413A CN 00811141 A CN00811141 A CN 00811141A CN 1156462 C CN1156462 C CN 1156462C
Authority
CN
China
Prior art keywords
formula
compound
atom
compounds
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008111413A
Other languages
English (en)
Chinese (zh)
Other versions
CN1367783A (zh
Inventor
R
R·布瓦格格赖恩
M·布里
P·莱尔
R·保罗
M·庞塞莱特
ά
J·－C·维尼雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of CN1367783A publication Critical patent/CN1367783A/zh
Application granted granted Critical
Publication of CN1156462C publication Critical patent/CN1156462C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB008111413A 1999-07-02 2000-06-27 抗精神病的环状n-芳烷基胺 Expired - Fee Related CN1156462C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/08532 1999-07-02
FR9908532A FR2795724B1 (fr) 1999-07-02 1999-07-02 Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
CN1367783A CN1367783A (zh) 2002-09-04
CN1156462C true CN1156462C (zh) 2004-07-07

Family

ID=9547628

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008111413A Expired - Fee Related CN1156462C (zh) 1999-07-02 2000-06-27 抗精神病的环状n-芳烷基胺

Country Status (31)

Country Link
US (1) US6908914B1 (enExample)
EP (1) EP1196403B1 (enExample)
JP (1) JP4931309B2 (enExample)
KR (1) KR100760446B1 (enExample)
CN (1) CN1156462C (enExample)
AR (1) AR029374A1 (enExample)
AT (1) ATE309231T1 (enExample)
AU (1) AU778299B2 (enExample)
BG (1) BG65209B1 (enExample)
BR (1) BR0012463B1 (enExample)
CA (1) CA2376691C (enExample)
CO (1) CO5021196A1 (enExample)
CZ (1) CZ300936B6 (enExample)
DE (1) DE60023898T2 (enExample)
DK (1) DK1196403T3 (enExample)
EA (1) EA004048B1 (enExample)
ES (1) ES2250160T3 (enExample)
FR (1) FR2795724B1 (enExample)
HK (1) HK1043122A1 (enExample)
HR (1) HRP20010949B1 (enExample)
HU (1) HU228983B1 (enExample)
IL (2) IL147069A0 (enExample)
ME (1) MEP25508A (enExample)
MX (1) MXPA01013207A (enExample)
NO (1) NO322230B1 (enExample)
NZ (1) NZ516342A (enExample)
RS (1) RS50266B (enExample)
TW (1) TWI285640B (enExample)
UA (1) UA71009C2 (enExample)
WO (1) WO2001002380A1 (enExample)
ZA (1) ZA200200018B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327673T1 (de) * 2001-08-23 2006-06-15 Bayer Cropscience Sa Substituierte propargylamine
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790971A (fr) * 1971-11-09 1973-05-07 Janssen Pharmaceutica Nv Metode ter voorkoming van patologische reakties die de funktie van het komplement vereisen
JPS504086A (enExample) * 1973-01-18 1975-01-16
US4104383A (en) * 1973-11-02 1978-08-01 C M Industries Derivatives of phenylpropenylamine
GB1475314A (en) * 1973-11-02 1977-06-01 Cm Ind Phenyl-propylamine derivatives
US4855462A (en) * 1988-06-17 1989-08-08 Pennwalt Corporation Antihistamines
EP0347123A3 (en) * 1988-06-17 1991-07-03 Fisons Corporation Dibenzo-cycloheptenyl, -cycloheptyl and -oxepinyl amines having antihistaminic properties
US4912222A (en) * 1988-06-17 1990-03-27 Fisons Corporation Antihistamines related to cyproheptadine
FR2663328B1 (fr) * 1990-06-14 1994-08-05 Sanofi Sa Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1993000313A2 (en) * 1991-06-27 1993-01-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JP3199405B2 (ja) * 1991-08-30 2001-08-20 生化学工業株式会社 肝細胞球状集塊化剤及び球状集塊化肝細胞の製造方法
US5486517A (en) * 1994-05-10 1996-01-23 Warner-Lambert Company Benzimidazoles and imidazopyridines as central nervous system agents
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
TR199902283T2 (xx) * 1997-03-18 1999-12-21 Smithkline Beecham P.L.C. �kame edilmi� izokuinolin t�revleri ve bunlar�n antikonvulsant olarak kullan�m�.

Also Published As

Publication number Publication date
NO20016392D0 (no) 2001-12-27
US6908914B1 (en) 2005-06-21
BR0012463A (pt) 2002-04-02
MEP25508A (en) 2010-06-10
ATE309231T1 (de) 2005-11-15
CN1367783A (zh) 2002-09-04
CZ300936B6 (cs) 2009-09-16
ES2250160T3 (es) 2006-04-16
NZ516342A (en) 2003-08-29
EA200101209A1 (ru) 2002-06-27
ZA200200018B (en) 2003-01-02
HUP0202200A3 (en) 2002-12-28
RS50266B (sr) 2009-07-15
DE60023898D1 (de) 2005-12-15
FR2795724A1 (fr) 2001-01-05
AU5992400A (en) 2001-01-22
EP1196403A1 (fr) 2002-04-17
HK1043122A1 (zh) 2002-09-06
CA2376691C (en) 2009-09-01
CA2376691A1 (en) 2001-01-11
HRP20010949A2 (en) 2003-04-30
HU228983B1 (en) 2013-07-29
JP4931309B2 (ja) 2012-05-16
YU91101A (sh) 2004-09-03
AU778299B2 (en) 2004-11-25
BR0012463B1 (pt) 2014-11-04
WO2001002380A8 (fr) 2001-06-28
AR029374A1 (es) 2003-06-25
FR2795724B1 (fr) 2002-12-13
EA004048B1 (ru) 2003-12-25
DE60023898T2 (de) 2006-08-10
PL356186A1 (en) 2004-06-14
NO20016392L (no) 2002-03-04
HRP20010949B1 (en) 2006-06-30
TWI285640B (en) 2007-08-21
IL147069A (en) 2006-09-05
KR20020016877A (ko) 2002-03-06
BG106255A (en) 2002-10-31
KR100760446B1 (ko) 2007-10-04
HUP0202200A2 (en) 2002-10-28
DK1196403T3 (da) 2006-03-20
WO2001002380A1 (fr) 2001-01-11
JP2003503487A (ja) 2003-01-28
EP1196403B1 (fr) 2005-11-09
MXPA01013207A (es) 2002-06-21
BG65209B1 (bg) 2007-07-31
UA71009C2 (uk) 2004-11-15
NO322230B1 (no) 2006-08-28
CO5021196A1 (es) 2001-03-27
CZ20014697A3 (cs) 2002-04-17
IL147069A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
CN1210250C (zh) 苯衍生物、其制备方法以及含有它们的药用组合物
CN1153764C (zh) 取代的苄氨基哌啶化合物
CN1020093C (zh) 1-苯基-3-萘氧基丙胺的制备方法
CN1178911C (zh) 吡咯烷与哌啶衍生物和它们用于治疗神经变性疾病的用途
CN1006464B (zh) 萘衍生物的制备方法
CN1636967A (zh) 新颖化合物，其用途及制法
CN1079219A (zh) 芳基乙酰胺
CN1610664A (zh) 3－氮杂二环[3.1.0]己烷衍生物作为类阿片受体拮抗剂
CN1154483C (zh) 胺化合物用于制备阻止肿瘤细胞增殖的药物
CN1183098C (zh) 3-氨基-3-芳基丙-1-醇衍生物及其制备和应用
CN1094039A (zh) 芳酰胺衍生物
CN1156462C (zh) 抗精神病的环状n-芳烷基胺
CN1226886A (zh) 芳基环烷甲酸酯、其用途、药物组合物和制备方法
CN1021051C (zh) 新型的噻吩衍生物的制备方法
CN86106294A (zh) 二氢吡啶类的制备方法
CN1423637A (zh) 新的取代的三环化合物
CN1067044C (zh) 新的三环衍生物和它们的制备方法
CN1547575A (zh) 新颖苯基烷基二胺和酰胺类似物
CN1049662A (zh) 香豆素衍生物及其制备和在治疗脑血管失调中的应用
CN1671647A (zh) 光学活性的1－(氟－、三氟甲基－或三氟甲氧基－取代的苯基)烷基胺n－单烷基衍生物及其制备方法
CN1034709A (zh) 取代的苯乙烯衍生物
CN1083055A (zh) 药剂
CN1247523C (zh) 取代1－和2－萘酚曼尼希碱
CN85104330A (zh) 胺衍生物的制备方法和含胺衍生物的杀真菌剂
CN100338037C (zh) 新的苯甲酰基哌啶化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SANOFI - AVENTIS

Free format text: FORMER NAME OR ADDRESS: ST. SANOFI - SYNTHELABO CORPORATION

CP01 Change in the name or title of a patent holder

Address after: Paris France

Patentee after: SANOFI-AVENTIS

Address before: Paris France

Patentee before: Sanofi-Synthelabo

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040707

Termination date: 20150627

EXPY Termination of patent right or utility model